Skip Main Navigation
Page Content

Office for Science and Technology at the Embassy of France in the USA

Innovation is the main economic driving force of the New England economy, and many indicators testify of this vitality: Massachusetts stands among the six leading states, as far as new technologies and innovation are concerned. The excellence of research that is performed in universities, as well as the ambitious public programs designed to support the development of new technologies, and a dynamic community of investors and entrepreneurs, are the ferments of New England’s economic success. France also deserves its reputation as one of the world’s leading countries in terms of research and academic excellence, which explains the importance of our cooperation with New England. 

The Office for Science and Technology’s mission consists in fostering cooperation between companies, entrepreneurs and actors of research and technology transfer on both sides of the Atlantic, and in supporting initiatives that facilitate collaborations in research and innovation.

Founded in 1964 the French National Institute of Health and Medical Research (Inserm) is the only public French science and technological institute dedicated to biological and medical research to improve human health, boasting over 15,000 researchers, engineers, and technicians.  Operating under the joint authority of the French Ministry of Health and the French Ministry of Research, Inserm took on the responsibility for the strategic, scientific, and operational coordination of biomedical research. Inserm distinguishes itself by being able to lead a multi-thematic approach to human conditions, guiding the healing and treatment processes from the research laboratories to patients’ bedsides, fostering an intimate understanding of both the most frequent and rarest of human ailments. Inserm is also a member of AVIESAN (The National Alliance of Health and Life Sciences) created in 2009, which groups together the prestigious French organizations and establishments including CEA, CNRS, CHRU, CPU, INRA, INRIA, Institut Pasteur, and IRD.

More information can be found at

Founded in 2000, InsermTransfert SA is the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), dedicated to technology transfer (from invention disclosure to industrial partnership). Inserm Transfert also manages European and International research projects, supports large scale projects in epidemiology and public health. Inserm Transfert runs a €2 million annual proof of concept fund. The company also supports entrepreneurs in the biotech sector, in partnership with Inserm Transfert Initiative, a €39.7 million life sciences seed investment company.

Inserm Transfert Initiative is a seed-capital company that has raised €35.5 million in new funding in 2012. It focuses on providing seed capital for innovative young companies in the biomedical field. Inserm Transfert Initiative was created in 2005 through an equal partnership between four providers of finance to biotech start-ups: Inserm Transfert SA, CDC Entreprises, Natexis Venture Selection and Sofinnova Partners. Inserm Transfert Initiative supports biotech entrepreneurs in the early stages of their companies' development.

Save This Event

Event Saved